NCT05482464

Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Oregon State University · Academic / Other
• Sex: All
• Age: 18 Years – 30 Years
• Healthy volunteers: Not accepted

Summary

This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).

Detailed description

In vitro assays show that GMP strongly promotes the growth of beneficial bacteria including Bifidobacterium breve, B. bifidum, B. infantis and Lactococcus lactis. GMP also binds to pathogenic bacteria and prevents their adhesion to intestinal cells, which could prevent enteric infection. GMP also modulates the inflammatory response of key gut immune cells called macrophages. However, the extent to which daily consumption of GMP alters the gut microbiome, metabolome and protein profile of subjects with IBS remains unknown. This study will investigate how daily GMP consumption can alter the gut microbiome, metabolome and protein profile of subjects with IBS.

Conditions

• Inflammatory Bowel Syndrome

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Casein glycomacropeptide (CGMP)	Casein glycomacropeptide (CGMP) supplementation for 3 weeks

Timeline

• Start date: 2022-01-01
• Primary completion: 2024-09-01
• Completion: 2024-09-01
• First posted: 2022-08-01
• Last updated: 2025-04-04

Locations

1 site across 1 country: United States